globenewswire.com · 2 jul

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

seekingalpha.com · 30 jun

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data. We still need to wait to see their placebo-controlled data, as well as their combo therapy data.

zacks.com · 29 jun

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.

zacks.com · 29 jun

Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company is focused on inflammatory bowel disease, or IBD, where it is developing long-acting antibodies and antibody combinations aimed at improving disease control, convenience and durability of response.

zacks.com · 29 jun

SYRE and Spyre Ride New IBD Trends in Biotech Drug Design

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

seekingalpha.com · 26 jun

Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcerative colitis validate SYRE's approach, with a third monotherapy readout and multiple rheumatology catalysts expected in 2026. SYRE's $1.18B cash position funds operations into 2H 2029, supporting robust clinical execution and mitigating near-term dilution risk.

etftrends.com · 25 jun

Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

reuters.com · 15 jun

Spyre says bowel disease drug cuts inflammation in mid-stage trial

Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ​reducing disease severity in a mid-stage trial.